<DOC>
	<DOC>NCT02667561</DOC>
	<brief_summary>This is a Phase I, open-label, parallel trial to evaluate Pharmacokinetics, Pharmacodynamics and Safety of Testosterone gel 1% for topic usage in post-menopausal women, for 28 days</brief_summary>
	<brief_title>Pharmacokinetics, Pharmacodinamic and Safety of Testosterone Gel 1%</brief_title>
	<detailed_description>This is a Phase I, open-label, parallel trial to evaluate Pharmacokinetics, Pharmacodynamics and Safety of Testosterone gel 1% for topic usage in post-menopausal women, Study participants will receive investigational product for 28 consecutive days, once daily, as per the following allocation: 2.2 mg, 4.4 mg. 8.8 mg or placebo.</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Female subjects aged ≥ 42 years and ≤ 65 years, in postmenopausal period for at least 1 year and with active sexual life; Serum testosterone levels &lt; 33 ng/mL; Folliclestimulating hormone (FSH) levels &gt; 22 mU/mL; Absence of other significant diseases which, at the physician's discretion, could impact subject's participation in the trial, according to protocol requirements, and study evaluations: medical history, blood pressure and heart rate measurements, physical examination and complimentary laboratory tests; Ability to understand the nature and objective of the trial, including risks and adverse events, which shall be confirmed by Informed Consent Form signature. Screening laboratory tests results presenting clinically relevant deviations that, at the investigator discretion, prevent the subject to participate in the trial due to possible risks; Drugs addiction, including alcohol; Treatment with any drugs known to have a wellestablished toxic potential to major organs, within 3 months before the trial, ; Participation in any other experimental research or administration of any experimental drug within six months before the initiation of this trial; Pregnancy, labor or miscarriage in the last 12 weeks before the antecipated date of the study treatment start; Any conditions, according to investigator's best judgement, that prevents the subject to participate in the trial.</criteria>
	<gender>Female</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>